Natera, Inc. is a U.S.-based molecular diagnostics company specializing in cell-free DNA (cfDNA) analysis. It develops and commercializes tests for oncology, women’s health, and organ health that support risk assessment, disease monitoring, and clinical decision-making.
Core products include Signatera, a personalized, tumor-informed circulating tumor DNA assay used to detect minimal residual disease and monitor cancer recurrence; Panorama, a noninvasive prenatal test; Horizon, a carrier screening panel; and Prospera, a cfDNA test for transplant rejection assessment. Natera applies next-generation sequencing and proprietary bioinformatics to analyze cfDNA from blood, and collaborates with hospitals, laboratories, and biopharma partners for clinical use, research, and companion diagnostic development.
None yet. When a new project in the record names Natera as owner, partner or investor, it shows here.
FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
Tecentriq reduces death risk by 41% and recurrence by 36% in bladder cancer using ctDNA guidance, sparing low-risk patients from unnecessary treatment.
